Brian Rini

Dr. Tom Powles and Dr. Brian Rini discuss 2023 updates for localized bladder cancer, including diagnostic workup, staging, and treatment options. They share mixed opinions on a trial and challenges in therapy, express skepticism towards PET scans, and explore various treatment options. Exciting insights from the urologic oncology experts!

Join oncologists Dr. Tom Powles and Dr. Brian Rini as they dive into the latest strategies for managing metastatic renal cell carcinoma. They discuss the importance of risk stratification and patient characteristics in treatment selection. The conversation covers the evolving role of cytoreductive nephrectomy, the significance of immunotherapy breaks, and the complexities of side effects from tyrosine kinase inhibitors. Listen for insights on tailored approaches for various RCC subtypes and career advice for budding oncologists!

Dr. Tom Powles and Dr. Brian Rini discuss 2023 updates for metastatic bladder cancer, including staging, treatment options, and variant histologies. They highlight the efficacy and adverse event profile of single agent pembrolizomab and mabidotin. The podcast also covers new drugs in oncology and treatment options for urethral carcinoma. Additionally, they discuss less common histologic types of bladder cancer and the challenges of variant histologies for personalized treatment approaches.

Join renowned oncologists Tom Powles, a leading expert in GU oncology from Barts Cancer Center, and Brian Rini, a pioneer in clinical trials at Vanderbilt, as they delve into the latest insights on localized renal cell carcinoma. They explore critical risk factors, including smoking and genetic conditions like von Hippel-Lindau syndrome. The duo examines evolving treatment strategies, including nephrectomy, ablative techniques, and the emerging role of immune therapies, shedding light on their potential impacts on patient outcomes.

Dr. Tom Powles and Dr. Brian Rini, experts in urologic oncology and renal cell carcinoma, delve into groundbreaking updates for metastatic kidney cancer. They discuss the IMDC classification and its role in risk assessment, emphasizing patient selection for treatments. Treatment strategies, including the balance between aggressive therapies and patient well-being, are explored. The duo also addresses challenges in non-clear cell variants and highlights the potential of emerging therapies. Finally, they share valuable advice for early-career oncologists, stressing the importance of mentorship.